Jeffrey L. Cleland,Stephen P. Eisenberg,Mary S. Rosendahl,Matthew B. Seefeldt
申请号：
US13560979
公开号：
US20130058895A1
申请日:
2012.07.27
申请国别(地区):
US
年份:
2013
代理人:
摘要：
Methods are provided using high pressure to treat aggregated interferons, to reduce the aggregate content of interferon material. In particular, recombinant human interferon-β may be so treated. Multiple strategies may be used in combination to make nonglycosylated IFN-β more amenable to high pressure treatment. When coupled with purification techniques, these strategies singly or in combination provide a low aggregate or substantially aggregate free, biologically active solution. In certain aspects, pharmaceutical compositions containing nonglycosylated interferon having less than about 5 weight percent of protein aggregation are provided.
